Answers are grounded in this paper and cite their sources.
Explores personalized transplantability in cholangiocarcinoma, suggesting refined selection enhances outcomes.
Liver transplantation for cholangiocarcinoma (CCA) shifted from a contraindication to a promising therapeutic option for selected patients. Advances in neoadjuvant therapy and refined selection criteria resulted in long-term outcomes comparable to other accepted oncologic indications, particularly in perihilar CCA managed with standardized protocols and in intrahepatic CCA with favorable tumor biology. The future challenge is to develop a multiparametric biological selection, blending clinical, functional, histopathologic, molecular, and radiologic parameters to identify candidates with indolent disease behavior, thus maximizing oncologic benefit while ensuring appropriate use of limited graft resources.
No takes yet. Share an insight, caveat, or question.
Cillo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: